Showing 1601-1610 of 2727 results for "".
- Interim IIT Data Explore Sculptra, Restylane for Menopause, Weight Loss–Related Aesthetic Changeshttps://modernaesthetics.com/news/interim-iit-data-explore-sculptra-restylane-for-menopause-weight-lossrelated-aesthetic-changes/2486595/Interim findings from 2 ongoing investigator-initiated trials supported by Galderma suggest potential roles for Sculptra and the Restylane portfolio in treating aesthetic changes associated with menopause and medication-driven weight loss. In one interim analysis led by Sabrina Fabi, MD, 2
- Merz Aesthetics Secures FDA Approval for RADIESSE in Décolleté Treatmenthttps://modernaesthetics.com/news/merz-aesthetics-secures-fda-approval-for-radiesse-in-decollete-treatment/2486550/Merz Aesthetics has received US Food and Drug Administration (FDA) approval for RADIESSE® (calcium hydroxylapatite [CaHA]) for the treatment of moderate to severe wrinkles in the décolleté in adults aged 22 years and older, according to a company announcement. The decision expands the
- Paper: AI Gains Ground in Cosmetic Dermatology Workflowshttps://modernaesthetics.com/news/paper-ai-gains-ground-in-cosmetic-dermatology-workflows/2486551/A recent review in Dermatology and Therapy assessed the growing use of artificial intelligence (AI) across aesthetic dermatology, with the authors reporting increased adoption and highlighting its use in many aspects of prac
- New Data Highlight How Ultrasound Imaging May Improve Safety in High-Risk Filler Injectionshttps://modernaesthetics.com/news/new-data-highlights-how-ultrasound-imaging-may-improve-safety-in-high-risk-filler-injections/2486532/The use of dermal fillers continues to expand across aesthetic practice, accompanied by ongoing concerns regarding vascular adverse events (VAEs), including tissue necrosis and vision loss. In a recent publication in Aesthetic Plastic Surgery, investigators evaluated the role of high-res
- Case Report Describes Dual-Phase CL Code for Facial Rejuvenationhttps://modernaesthetics.com/news/case-report-describes-dual-phase-cl-code-for-facial-rejuvenation/2486484/A case report in the April 2026 issue of Journal of Cosmetic Dermatology described a dual-phase injectable approach to facial rejuvenation that combined contour restoration with ligamentous support using a polycaprolactone-based collagen stimulator. The authors termed the method the “CL
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://modernaesthetics.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- SkinPen Milestone Highlights Growth in Microneedling Demandhttps://modernaesthetics.com/news/skinpen-milestone-highlights-growth-in-microneedling-demand/2486459/Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company’s microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the de
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://modernaesthetics.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://modernaesthetics.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A